National Liver Cancer Screening Trial

Key facts

Sponsor

University of Texas Southwestern Medical Center

Principal Investigator

Amit Singal, MD, MS

University of Texas Southwestern Medical Center

Intervention

GALAD(diagnostic_test)

Enrollment

5500 target

Eligibility

18-85 years · All sexes

Timeline

2023 – 2034

Study locations (18)

• University of Southern California, Los Angeles, California, United States
• Stanford University, Redwood City, California, United States
• Kaiser Permanente, Roseville, California, United States
• University of California, San Francisco, San Francisco, California, United States
• Northwestern University, Chicago, Illinois, United States
• Indiana University, Indianapolis, Indiana, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Henry Ford Health System, Detroit, Michigan, United States
• Hennepin Healthcare, Minneapolis, Minnesota, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• The Feinstein Institutes, Northwell Health, Inc., Manhasset, New York, United States
• University of North Carolina, Chapel Hill, North Carolina, United States
• Case Western Reserve University, Cleveland, Ohio, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• +3 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · University of Pennsylvania · University of Michigan · Dana-Farber Cancer Institute · Baylor College of Medicine · Fred Hutchinson Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06902246
  Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
  University of Miami
• RECRUITINGPHASE1NCT07419841
  A Phase 1 Study of the Safety and Tolerability of CTX-10726
  Compass Therapeutics
• RECRUITINGPHASE1NCT07493044
  An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
  Guangzhou FineImmune Biotechnology Co., LTD.
• RECRUITINGPHASE2NCT07122089
  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
  Center Eugene Marquis
• RECRUITINGPHASE1, PHASE2NCT07482059
  A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
  West China Hospital
• RECRUITINGPHASE2NCT06254248
  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNANCT07469319
  Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
  University of Aarhus
• RECRUITINGEARLY PHASE1NCT07242417
  TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
  Beijing GoBroad Hospital

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →